ArticleBMC microbiology2026
High prevalence of bla
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Enterobacterales are increasingly reported worldwide, posing significant treatment challenges, especially in vulnerable pediatric populations. This study describes the molecular epidemiology and antimicrobial susceptibility of carbapenem-resistant Enterobacterales isolated from infants under one year of age in Niger. This prospective case series reports on 14 children < 1 year old with carbapenem-resistant Enterobacterales isolates.
resultsA total of 14 isolates were analyzed, predominantly Escherichia coli (78.6%; n = 11), followed by Serratia odorifera (7.1%, n = 1), Klebsiella pneumoniae (7.1%, n = 1), and Klebsiella oxytoca (7.1%, n = 1). The blaNDM gene was the most frequently detected carbapenemase, found in 7 isolates (50.0%), followed by blaVIM in 4 isolates (28.6%), blaKPC in 2 isolates (14.3%), and blaOXA−48 in 1 isolate (7.1%). High resistance rates to fluoroquinolones and aminoglycosides were observed, with moderate fosfomycin activity. Cefiderocol, tigecycline, and eravacycline demonstrated preserved activity across carbapenemase genotypes, whereas ceftazidime–avibactam showed limited activity against metallo-β-lactamase producers. An apparent relationship between carbapenemase genotype and multidrug resistance phenotype was observed.
conclusionsCarbapenem-resistant Enterobacterales isolates in infants under one year of age represent a major clinical challenge in Niger. The predominance of blaNDM producing organisms, combined with high levels of resistance to commonly used antibiotics, limits the effectiveness of standard empirical therapies. Cefiderocol and tetracycline derivatives exhibit promising activity and may inform treatment strategies where available. Regional differences in carbapenemase epidemiology underscore the need for enhanced surveillance and stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.